<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28633">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02733978</url>
  </required_header>
  <id_info>
    <org_study_id>Assuit Ozone</org_study_id>
    <nct_id>NCT02733978</nct_id>
  </id_info>
  <brief_title>Ozone Therapy in the Treatment of Digital Ulcers in Patients With Systemic Sclerosis</brief_title>
  <official_title>Non-invasive Oxygen-Ozone Therapy in the Treatment of Digital Ulcers in Egyptian Patients With Systemic Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Digital ulcers (DUs) in scleroderma result from recurrent Raynaud's phenomenon (RP) and
      microtrauma with high impact on quality of life, management of DUs is a great challenge for
      clinicians. Medical use of ozone (triatomic oxygen) was initiated in the 19th century. Ozone
      has multiple therapeutic effects in wound healing due to the property of releasing nascent
      oxygen, which has been shown to stimulate antioxidant enzymes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Digital ulcers (DUs) in scleroderma result from recurrent Raynaud's phenomenon (RP) and
      microtrauma with high impact on quality of life, management of DUs is a great challenge for
      clinicians. Medical use of ozone (triatomic oxygen) was initiated in the 19th century. Ozone
      has multiple therapeutic effects in wound healing due to the property of releasing nascent
      oxygen, which has been shown to stimulate antioxidant enzymes, we aim to assess the effects
      of ozone therapy on the healing in Scleroderma DUs and the expressions of vascular
      endothelial growth factor (VEGF), and endothelin-1 type A receptor (ETAR) and angiotensin II
      type 1 receptor (AT1R) autoantibodies level in the wounds after treatment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>scleroderma ulcer healing</measure>
    <time_frame>4 months</time_frame>
    <description>Ulcer size measurement in cm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain</measure>
    <time_frame>4 months</time_frame>
    <description>Using 10 cm scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ulcer biopsy</measure>
    <time_frame>4 months</time_frame>
    <description>Biopsy from the ulcer edge</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Ulcer</condition>
  <condition>Scleroderma</condition>
  <arm_group>
    <arm_group_label>ozone treated group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Therapeutic effects will be graded into 4 levels from grade 0 (no change) to grade 3 (wound healing). The wound sizes will be measured at baseline and day 20, respectively. Tissue biopsies will be performed at baseline and day 20, expressions of VEGF, ETAR and AT1R autoantibodies proteins will be determined by immune-histochemical examinations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-ozone treated group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Therapeutic effects will be graded into 4 levels from grade 0 (no change) to grade 3 (wound healing). The wound sizes will be measured at baseline and day 20, respectively. Tissue biopsies will be performed at baseline and day 20, expressions of VEGF, ETAR and AT1R autoantibodies proteins will be determined by immune-histochemical examinations</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>the ozone generator device (Human Pro medic, German)</intervention_name>
    <description>noninvasive oxygen-ozone treatments with 52 ug/mL ozone (total volume: 20-50 mL) in a special bag for 30 min per day for 20 days using the ozone generator device (Human Pro Medic, German)</description>
    <arm_group_label>ozone treated group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  systemic sclerosis patients with DUs fulfilling ACR/EULAR criteria for diagnosis 2013

        Exclusion Criteria:

          -  calcinosis ulcer traumatic ulcer vasculitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sonya M Rashad, professor</last_name>
    <phone>+2 01006240961</phone>
    <email>souniarashad@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>arwa S Algohee, Dr</last_name>
    <phone>+2 01018961640</phone>
    <email>dr.al_joohi@yahoo.com</email>
  </overall_contact_backup>
  <link>
    <url>http://dx.doi.org/10.1155/2014/273475</url>
  </link>
  <results_reference>
    <citation>Elvis AM, Ekta JS. Ozone therapy: A clinical review. J Nat Sci Biol Med. 2011 Jan;2(1):66-70. doi: 10.4103/0976-9668.82319.</citation>
    <PMID>22470237</PMID>
  </results_reference>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>April 6, 2016</lastchanged_date>
  <firstreceived_date>March 25, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Manal Hassanien</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>Ozone oxygen</keyword>
  <keyword>ulcer healing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
